Artax Biopharma is transforming the treatment of T Cell mediated disease.
Employees: 11-50
Total raised: $36M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Keith Vent... | keith.vc/ |
| - | Advent Lif... | adventls.c... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 11.05.2022 | - | $26M | - | finsmes.co... |
| 22.09.2015 | Series B | $10M | - | medcitynew... |
Mentions in press and media 10
| Date | Title | Description | Source |
| 12.05.2022 | Artax Biopharma Closes $26M Financing Round | Artax Biopharma, a Cambridge, MA-based clinical stage biotechnology company, raised $26M in funding.... | finsmes.co... |
| 12.05.2022 | Columbus VP cierra la financiación de $26M en Artax Biopharm... | 12/05/2022 Nota de prensa COLUMBUS CIERRA LA FINANCIACIÓN EN LA EMPRESA ARTAX BIOPHARMA. La firma... | webcapital... |
| 11.05.2022 | Artax Biopharma Closes $26M Financing | CAMBRIDGE, MA, Artax Biopharma, a clinical stage biotechnology company, has announced the close of... | vcnewsdail... |
| 11.05.2022 | A Y Combinator alum on how the startup hustle came at a stee... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 17.09.2020 | Artax Biopharma Announces Issuance of U.S. Composition of Ma... | CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Artax Biopharma, Inc., a biotechnology company fo... | prnewswire... |
| 05.06.2020 | Artax Biopharma Raises Series B Financing Extension | Artax Biopharma, Inc., a Cambridge, Mass.-based biotechnology company focused on transforming autoim... | finsmes.co... |
| 22.09.2015 | La biotecnológica Artax Biopharma cierra una ronda de $10 mi... | 22/09/2015 LA BIOTECNOLÓGICA ARTAX BIOPHARMA CIERRA UNA RONDA DE $10 MILLONES. La startup biotecno... | webcapital... |
| 22.09.2015 | Artax Biopharma Raises $10M in Series B Funding | Artax Biopharma, a Cambridge, Massachusetts-based clinical stage biotechnology company developing se... | finsmes.co... |
| 22.09.2015 | Artax raises $10M Series B for autoimmune disease small mole... | The underlying technology comes from Spanish National Council researcher Dr. Balbino Alarcon. He’ll ... | medcitynew... |
| - | Artax raises $10M Series B for autoimmune disease small mole... | Former Genzyme CEO Henri Termeer led a new investment round for Artax Biopharma, a Cambridge startup... | medcitynew... |